NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies.

NorthStar Medical Radioisotopes has promoted Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies. (Photo: Business Wire)

April 13, 2023 —NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic and medical imaging applications, has announced the promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies. Vinyard, who has been with NorthStar since 2021, was previously Senior Director, Business Development, Therapeutic Technologies, for the Company. He has more than 22 years of operational and commercial expertise in radioisotopes and radiopharmaceuticals. In this new position, Mr. Vinyard will have responsibility to advance the successful commercialization and market implementation of therapeutic radioisotopes, including copper-67 (Cu-67) and non-carrier added (n.c.a.) actinium-225 (Ac-225), and drive business development initiatives for NorthStar’s Radiopharmaceutical CDMO/CMO business units. He will report to NorthStar President and Chief Operating Officer Frank Scholz, Ph.D. 

“It’s a great pleasure to recognize Jason’s many contributions to NorthStar’s progress with this promotion,” said Scholz. “Demand for therapeutic radiopharmaceuticals is increasing rapidly, and NorthStar is at the forefront of being able to produce commercial-scale supply of n.c.a. Ac-225 and Cu-67 using environmentally preferable technologies. Jason’s depth of knowledge and leadership in the radiopharmaceutical sector have already proven to be great assets in driving our business development activities, as evidenced by the fact that NorthStar has now signed multiple publicly announced supply agreements for n.c.a. Ac-225. We anticipate further growth in the therapeutic radioisotopes area and with our recently announced full-scale Radiopharmaceutical CDMO/CMO services unit, and we are confident that Jason’s efforts will be integral to identifying new business opportunities as we continue progressing our mission to provide patients with global access to game-changing radiopharmaceuticals.” 

"I am proud to be working with NorthStar during this dynamic time of growth and opportunity for the Company and the nuclear medicine community,” said Vinyard. “NorthStar has an industry-leading reputation based on its technological innovation, successful execution and proven expertise. I look forward to building new relationships and expanding our collaborations with companies that seek reliable therapeutic radioisotopes supply or Radiopharmaceutical CDMO/CMO services, to help them meet patients’ healthcare needs.” 

Prior to joining NorthStar, Vinyard spent 16 years in roles of increasing responsibility at Mallinckrodt/Curium, where he was most recently Global Director of Business Development for Curium’s Active Pharmaceutical Ingredient business and held responsibility for a considerable portion of its U.S. SPECT franchise. Earlier in his career, he held operational responsibilities for facility management of isotope production with Regional Nuclear Pharmaceuticals (now Cardinal Health). Mr. Vinyard holds a Masters in Business Administration and a Masters in Healthcare Administration from the University of St. Francis in Joliet, Ill., and a Bachelor of Science degree from Jacksonville State University. 

For more information: 

Related Radioisotope Content:
NorthStar Medical Radioisotopes Announces Supply Agreement with Aktis Oncology, Inc. for Alpha-Emitting Therapeutic Radioisotope Actinium-225 (Ac-225)   
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)     
Update on HFR Reactor Outage – Medical Isotope Supply Returning to Normal     
Update on Unplanned Outage of the HFR Reactor     
SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply    
NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals     
How Nuclear Fusion is Revolutionizing Medical Isotope Production     
FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes     
Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE     
IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m  

Related Content

Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
News | SNMMI

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
News | PET-CT

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

Time September 08, 2023
Feature | PET Imaging

According to a new report from Transparency Market Research (TMR), PET radiotracers are expected to rise at a CAGR of 8 ...

Time September 05, 2023
News | Radiopharmaceuticals and Tracers

August 31, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 31, 2023
News | Radiopharmaceuticals and Tracers

August 29, 2023 — Mammograms are an essential part of preventive healthcare, and when an initial review reveals a ...

Time August 29, 2023
News | Radiation Therapy

August 23, 2023 — RefleXion Medical, a therapeutic oncology company, today announced that the first patient has ...

Time August 23, 2023
News | Contrast Media

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Time August 17, 2023
Subscribe Now